Important information regarding cookies and
By using this website, you consent to the use of cookies in accordance with the IMB Cookie Policy. For more information on cookies, see our Cookie Policy.
Full Version | Search

The Irish Medicines Board -

IMB Logo

European Medicines Agency (EMA) completes its review of Avastin (bevacizumab) used in breast cancer treatment

20 December 2010

Categories: News

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that Avastin, when used to treat metastatic breast cancer, should only be used in combination with the taxane paclitaxel. This follows a review of Avastin in combination with taxanes, where the Committee concluded that Avastin should no longer be used in combination with another taxane, docetaxel. The Committee also adopted a negative opinion on the proposed use of Avastin in combination with capecitabine in metastatic breast cancer.

Further information, including recommendations for patients and prescribers, is available at the links below:

Press release on European Medicines Agency website

Q & A document on European Medicines Agency website

Date Printed: 20 April 2014

© Irish Medicines Board 2014 | Developed by Engine Solutions

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971